Business Context and Reporting Period
This Form 8-K was filed by Relmada Therapeutics, Inc. on October 13, 2022. The filing serves as a Regulation FD disclosure and reports on the top-line results of the Company's Phase 3 RELIANCE III clinical trial for its lead candidate, REL-1017, intended as a monotherapy for Major Depressive Disorder (MDD).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
- Primary Endpoint Failure: The RELIANCE III study (REL-1017-303) did not achieve its primary endpoint of statistically significant improvement in depression symptoms compared to placebo on Day 28.
- Efficacy Data: The REL-1017 treatment arm showed a Montgomery-Asberg Depression Rating Scale (MADRS) reduction of 14.8 points at Day 28, compared to 13.9 points for the placebo arm.
- Placebo Response: The Company attributed the lack of statistical significance to a higher than expected placebo response.
- Study Population: The trial involved 232 subjects treated for 28 days.
Outlook, Safety, and Management Commentary
- Safety Profile: REL-1017 demonstrated very favorable tolerability and safety. Notable findings included no opioid-like effects, no withdrawal effects, and no psychotomimetic effects.
- Cardiac Safety: There were no adverse events related to QTcF prolongation.
- Future Guidance: The filing does not provide specific financial guidance or a revised timeline for future development steps beyond the announcement of these results.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis and p-values regarding the primary endpoint failure.
- Review the Company's most recent 10-Q or 10-K to assess current cash runway and liquidity given the negative clinical outcome.
- Monitor subsequent filings for management's strategic plan regarding the future development of REL-1017 or potential pivots in the MDD program.
- Check for any analyst downgrades or changes in institutional ownership following the announcement.